Article

Unoprostone lowers IOP in advanced glaucoma cases

Washington, DC-Unoprostone isopropyl 0.15% (Rescula, Novartis) may be a viable option for further lowering IOP in patients with advanced glaucoma whose disease is uncontrolled by maximum tolerated medical therapy, said Leslie S. Jones, MD.

Related Videos
(Image credit: Ophthalmology Times) Thomas W. Samuelson, MD, shares clinical perspectives on DSLT, SLT, and glaucoma management
Related Content
Telomir-1 exhibited strong ROS reduction properties, hold potential for AMD treatment
February 23rd 2025

Telomir-1 exhibited strong ROS reduction properties, hold potential for AMD treatment

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Retinal detachment risk after B1KPro
February 22nd 2025

Retinal detachment risk after B1KPro

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Sexual harassment remains high in ophthalmology
February 21st 2025

Sexual harassment remains high in ophthalmology

Heart Eye announces AI-driven retinal imaging system to detect biomarkers of cardiovascular health risks
February 21st 2025

Heart Eye announces AI-driven retinal imaging system to detect biomarkers of cardiovascular health risks

© 2025 MJH Life Sciences

All rights reserved.